Anti-CD3-anti-CD19 bispecific monoclonal antibody

Drug Profile

Anti-CD3-anti-CD19 bispecific monoclonal antibody

Alternative Names: Monoclonal antibody SHR-1

Latest Information Update: 10 Apr 2003

Price : $50

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in Netherlands (IV-infusion)
  • 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top